human dopaminergic progenitor cells
Cell therapyexperimental
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2023 (NCT06167681)
Timeline
Indications
Studied for
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07289477 | Phase 1 | Dec 31, 2025 | iRegene Therapeutics Co., Ltd. |
| NCT07102342 | Phase 1 | Oct 31, 2025 | iRegene Therapeutics Co., Ltd. |
| NCT07166757 | Phase 1/Phase 2 (Phase 2) | Sep 22, 2025 | Government of China |
| NCT07080775 | Phase 1 | Aug 5, 2025 | Capital Medical University, Government of China |
| NCT07028632 | Phase 2 | Jun 30, 2025 | iRegene Therapeutics Co., Ltd. |
| NCT06687837 | Phase 1 | Dec 31, 2024 | Harvard University |
| NCT06583291 | Early Phase 1 (Phase 1) | Oct 1, 2024 | Anhui Medical University |
| NCT06608355 | Phase 1 | Aug 23, 2024 | iRegene Therapeutics Co., Ltd. |
| NCT06167681 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | iRegene Therapeutics Co., Ltd. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| iRegene Therapeutics Co., Ltd. | For profit | 5 | 5 | 2 | 2023 |
| Government of China | Government | 2 | 2 | 2 | 2025 |
| Anhui Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2024 |
5 organizations
Page 1 / 1